Skip to content
6 physician-led programs. Know your costs before you begin.See what we treat
GLP-1 receptor agonist

Ozempic

semaglutide

FDA-approved for type-2 diabetes management. Once-weekly subcutaneous injection.

Mechanism

How it works

Ozempic is the same molecule as Wegovy (semaglutide), but its FDA approval is for type-2 diabetes rather than chronic weight management. It mimics a gut hormone that slows gastric emptying, reduces appetite, and supports insulin signaling.

Technical detail
Semaglutide is a long-acting GLP-1 receptor agonist with a half-life of approximately 7 days. In type-2 diabetes it produces glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, and central satiety effects.
At Vayra

How we use it

Ozempic is prescribed within the GLP-1 Weight Optimization program for patients with type-2 diabetes whose physician determines it is the appropriate FDA-approved option. We do not market Ozempic for weight loss, that indication belongs to Wegovy. Continuity is a priority, you will see the same physician whenever clinically possible.

Route & titration

What to expect

Once-weekly subcutaneous self-administered injection. Dose escalation per the diabetes label: 0.25 mg → 0.5 mg → 1.0 mg → 2.0 mg weekly, advancing approximately monthly per tolerance and glycemic response. Maximum on-label maintenance is 2.0 mg weekly.

Safety

Adverse effects and contraindications

Common
  • Nausea during titration
  • Diarrhea
  • Constipation
  • Reduced appetite
Infrequent
  • Headache
  • Injection-site irritation
Serious
  • Pancreatitis, discontinue if suspected
  • Gallbladder events
  • Hypoglycemia when used in combination with insulin or a sulfonylurea
  • Diabetic retinopathy progression in patients with established disease
  • Thyroid C-cell tumors, boxed warning per the FDA label
Contraindications
  • Personal or family history of medullary thyroid carcinoma or MEN-2 syndrome
  • Pregnancy or planned pregnancy in the next 2 months
  • Severe gastroparesis
Evidence

What the literature says

Published trials of semaglutide in type-2 diabetes (the SUSTAIN program) report HbA1c reduction and weight reduction. Vayra does not claim specific outcomes.

Dispensing

How it reaches you

Branded Ozempic is prescribed and dispensed through a separately licensed retail/specialty pharmacy partner. Your medication is priced separately and shown with your total, alongside your physician care and lab review.

Your health info stays private (HIPAA)
Licensed doctors in 40+ states
Filled by a licensed pharmacy
No insurance needed · Use your FSA or HSA

Begin a documented physician visit.

Prescribing is the outcome of a clinical encounter, not a checkout flow. Your assessment takes about eight minutes; nothing is billed until you and your physician agree on a protocol.

See if Vayra is right for you

Eight minutes to start. A lifetime of difference.

A Vayra-affiliated physician reviews your intake, typically within 24 to 48 hours. No insurance billed. No minimum term.